Details of the Drug Pharmacogenomic Perturbation Atlas

Erythromycin Drug Info

Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery

Therapeutic Class

Antibiotics

Cross-matching ID

PubChem CID

12560

ChEBI ID

CHEMBL532

CAS Number

CAS 114-07-8

TTD Drug ID

D02YIZ

VARIDT Drug ID

DR00050

INTEDE Drug ID

DR0614

ACDINA Drug ID

D00241

General Information of Drug (ID: DM4K7GQ)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.17	0.00e+0	34/36 (94.44%)	RFC2;MCM2;RPA2;...
Allograft rejection	2.11	0.00e+0	32/38 (84.21%)	HLA-DOB;HLA-DQA1;CD40;...
Graft-versus-host disease	2.09	0.00e+0	32/42 (76.19%)	HLA-DOB;HLA-DQA1;CD86;...
Autoimmune thyroid disease	2.05	0.00e+0	46/53 (86.79%)	HLA-DOB;HLA-DQA1;CD40;...
Type I diabetes mellitus	1.96	4.49e-3	38/43 (88.37%)	HLA-DOB;HLA-DQA1;CD86;...
Antigen processing and presentation	1.95	3.74e-3	60/78 (76.92%)	HLA-DOB;HLA-DQA1;TAPBP;...
Pentose phosphate pathway	1.91	8.01e-3	25/30 (83.33%)	PFKL;PFKM;RPIA;...
Intestinal immune network for IgA production	1.87	1.26e-2	38/48 (79.17%)	HLA-DOB;HLA-DQA1;CD40;...
Viral myocarditis	1.85	1.25e-2	53/60 (88.33%)	HLA-DOB;HLA-DQA1;CD40;...
Mismatch repair	1.83	1.46e-2	22/23 (95.65%)	RFC2;RPA2;RFC3;...
Cell cycle	1.81	1.73e-2	110/124 (88.71%)	CCND2;YWHAH;MCM2;...
Leishmaniasis	1.81	1.68e-2	67/77 (87.01%)	HLA-DOB;HLA-DQA1;FCGR2C;...
Epstein-Barr virus infection	1.79	1.55e-2	189/202 (93.56%)	OAS2;HLA-DOB;RELB;...
RIG-I-like receptor signaling pathway	1.74	2.24e-2	64/70 (91.43%)	ISG15;IFIH1;MAPK13;...
RNA degradation	1.74	2.24e-2	53/79 (67.09%)	PFKL;ENO2;BTG2;...
Asthma	1.71	2.31e-2	25/31 (80.65%)	HLA-DOB;HLA-DQA1;CD40;...
Primary immunodeficiency	1.70	2.18e-2	33/38 (86.84%)	CD40;IL7R;IL2RG;...
Glycolysis / Gluconeogenesis	1.68	2.99e-2	56/67 (83.58%)	PFKL;ENO2;PKM;...
Fructose and mannose metabolism	1.64	4.19e-2	30/33 (90.91%)	PFKL;TPI1;PMM2;...
Arginine and proline metabolism	1.62	4.94e-2	39/50 (78%)	CKB;ODC1;GATM;...
Cytosolic DNA-sensing pathway	1.62	4.70e-2	52/63 (82.54%)	CCL5;DDX58;CASP1;...
alpha-Linolenic acid metabolism	-1.72	4.04e-2	17/25 (68%)	PLA2G10;FADS2;PLA2G4C;...
Linoleic acid metabolism	-1.77	2.25e-2	21/29 (72.41%)	CYP1A2;PLA2G10;PLA2G4C;...
Glycerophospholipid metabolism	-1.78	2.62e-2	71/98 (72.45%)	GNPAT;DGKZ;LPGAT1;...
Fatty acid degradation	-1.78	3.14e-2	40/43 (93.02%)	ACSL1;ADH1A;ADH5;...
Ether lipid metabolism	-1.79	3.49e-2	32/49 (65.31%)	ENPP2;PLD3;PLA2G10;...
Arachidonic acid metabolism	-1.80	4.37e-2	48/61 (78.69%)	PTGDS;PLA2G10;TBXAS1;...
Complement and coagulation cascades	-2.03	4.37e-3	76/85 (89.41%)	VWF;FGA;C8B;...
Retinol metabolism	-2.18	0.00e+0	41/68 (60.29%)	ALDH1A3;RDH11;ALDH1A2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H